Globe Newswire (Tue, 21-Jan 8:15 AM ET)
Oragenics Announces Leadership Changes and Relocation
TipRanks (Fri, 17-Jan 4:29 PM ET)
Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference
Globe Newswire (Mon, 16-Dec 8:09 AM ET)
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
Oragenics trades on the AMEX stock market under the symbol OGEN.
As of January 21, 2025, OGEN stock price climbed to $0.29 with 571,857 million shares trading.
OGEN has a beta of 3.62, meaning it tends to be more sensitive to market movements. OGEN has a correlation of 0.06 to the broad based SPY ETF.
OGEN has a market cap of $3.63 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, OGEN traded as high as $29.99 and as low as $.25.
The top ETF exchange traded funds that OGEN belongs to (by Net Assets): VXF.
OGEN has underperformed the market in the last year with a price return of -95.0% while the SPY ETF gained +29.2%. OGEN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.4% and -16.5%, respectively, while the SPY returned +3.9% and +1.9%, respectively.
OGEN support price is $.25 and resistance is $.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OGEN shares will trade within this expected range on the day.